The molecule is also being tested in over 100 vaccine clinical trials. Rising QS-21 demand from the pharmaceutical industry ...

GSK is doubling production of its AS01 adjuvant – used to boost the immune response to vaccines – for use in the malaria shot as it anticipates rising demand, and will work through its ...

One example of this is GSK’s commitment to make its new malaria vaccine RTS,S affordable, the company planning to price it at £8.50 (10.42 US dollars) per child, based on demand of around 100 ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...

GSK’s full-year results for 2024 beat my personal expectations. Overall, 2024 sales grew 7% to £31bn, with speciality medicines up 19%. This helped offset a 4% drop in vaccine sales.

Scientists at Sanaria and Seattle Children's Research Institute's Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking malaria vaccine, Sanaria® PfSPZ-LARC2 Vaccine, ...